Showing 3671-3680 of 5773 results for "".
- Tarsus Presents Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Datahttps://modernod.com/news/tarsus-to-present-saturn-2-pivotal-phase-3-trial-data-and-saturn-1-extension-study-long-term-safety-data-at-upcoming-eye-care-meetings/2481123/Tarsus Pharmaceuticals announced that the results from the Saturn-2 pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) in Demodex blepharitis patients will be presented at the upcoming World Cornea Congress (WCC) VIII and the American Academy of Ophthalmology
- Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congresshttps://modernod.com/news/bausch-lomb-will-present-scientific-data-and-analyses-during-world-cornea-congress/2481119/Bausch + Lomb announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from September 28-29, 2022. 'The podium presentation will feature findings from the pivotal p
- EyeCare Partners Launches New Innovation Centerhttps://modernod.com/news/eyecare-partners-launches-new-innovation-center/2481118/EyeCare Partners (ECP) announced the launch of the EyeCare Partners Innovation Center, which aims to improve the delivery and quality of eye care and advance clinical eye health education. The Innovation Center will be led by ECP’s Chief Clinical Officer, Antonio Capone, Jr., MD.
- Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIIIhttps://modernod.com/news/oyster-point-pharma-to-present-new-scientific-analyses-at-world-cornea-congress-viii/2481117/Oyster Point Pharma announced it will present new scientific analyses at World Cornea Congress VIII, which is taking place in Chicago from September 28-29, 2022. “We look forward to presenting our post-hoc analyses on the clini
- Santen and UBE Receive FDA Approval for Omlonti for the Reduction of Elevated IOP in Patients with Primary Open-Angle Glaucoma or Ocular Hypertensionhttps://modernod.com/news/santen-and-ube-receive-fda-approval-for-omlonti-for-the-reduction-of-elevated-iop-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension/2481115/Santen and UBE announced that the FDA has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension. The approval date was September 22. Omi
- Amydis Enrolls First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Diseasehttps://modernod.com/news/amydis-announces-enrollment-of-first-participants-in-probe-a-phase-12a-trial-evaluating-a-novel-retinal-tracer-in-people-with-amyotrophic-lateral-sclerosis-or-parkinsons-disease/2481109/Amydis announced dosing of the first patients in the company’s phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients w
- Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001https://modernod.com/news/frontera-therapeutics-receives-additional-ind-clearance-for-its-lead-program-ft-001/2481106/Frontera Therapeutics announced that its lead program, FT-001, a gene therapy product candidate targeting inherited retinal degenerations (IRDs) with a RPE65 mutation, successfully obtained an IND from the Center for Drug Evaluation (CDE), NMPA, in China. The FDA also cleared an IND for
- Cimerli, First Biosimilar Interchangeable to Lucentis, Set to Launch in the UShttps://modernod.com/news/coherus-to-launch-cimerli-ranibizumab-eqrn-in-the-us/2481103/Coherus BioSciences announced the commercial availability, beginning October 3, 2022, of Cimerli (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all approved indications. Cimerli was approved by the FDA in August 2022, having met FDA&rs
- European Commission Approves Roche’s Vabysmo for Wet AMD and DMEhttps://modernod.com/news/european-commission-approves-roches-vabysmo-for-wet-amd-and-dme/2481102/Roche announced that the European Commission (EC) approved Vabysmo (faricimab) for the treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME). “Many people with nAMD and DME struggle to keep up with the mont
- Pixium Vision Reaches Enrollment Target in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-reaches-enrollment-target-in-the-european-pivotal-trial-primavera/2481101/Pixium Vision SA announced the completion of patient enrollment in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD), also known as geographic atrophy. A total of 38 patients have been enrolled in the PRIMAvera study